Polypid Stock News

The independent Data Safety Monitoring Board (DSMB) has recommended concluding enrollment in PolyPid Ltd's (NASDAQ: PYPD) SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections (S

PolyPid Ltd. (NASDAQ:PYPD ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a

PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdomina

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locall

PolyPid press release (PYPD): Q4 GAAP EPS of $0.71 beats by $1.25.Revenue of $9.48M (+87.4% Y/Y).

PolyPid (NASDAQ: PYPD ) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Check out this: Executives Buy Around $64M Of 3 Stocks Earnings PolyPid … Full story available on Benzinga.com

• FDA A greed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Co mplete their 30 - day F ollow-up • Recruitment Progressing as Planned with Approximately 6 80 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue S urgery . Expect to R each 750 E nrolled P atients by E nd of F irst Q uarter 2022 and H ave Unblinded Interim Analysis D uring the S econd Q uarter of 2022 • Recently Completed Planned 500 - P atient Blinded Sample Size Re a ssessment of SHIELD I Support s the C ontinuation of the T rial • Conference Call S cheduled for Today at 8:30 AM ET

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell Equinor (NYSE: EQNR ) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. ICL Group (NYSE: ICL ) is expected to report quarterly earnings at $0.13 per share on revenue of $1.82 billion. Madison Square Garden (NYSE: MSGE ) is projected to report quarterly earnings at $1.00 per share on revenue of $538.98 million. Anavex Life Sciences (NASDAQ: AVXL ) is likely to report earnings for its first quarter. Orion Energy Sys (NASDAQ: OESX ) is likely to report quarterly earnings at $0.04 per share on revenue of $32.86 million. Penske Automotive Group (NYSE: PAG ) is estimated to report quarterly earnings at $3.69 per share on revenue of $6.22 billion. Mastech Digital (AMEX: MHH ) is projected to report quarterly earnings at $0.38 per share on revenue of $59.90 million. Perion Network (NASDAQ: PERI ) is projected to report quarterly earnings at $0.39 per share on revenue of $144.96 million. Ares Capital (NASDAQ: ARCC ) is estimated to report quarterly earnings at $0.49 per share on revenue of $459.14 million. Lithia Motors (NYSE: LAD ) is expected to report quarterly earnings at $10.14 per share on revenue of $6.15 billion. Cameco (NYSE: CCJ ) is expected to report quarterly earnings at $0.03 per share on revenue of $362.39 million. CDW (NASDAQ: CDW ) is expected to report quarterly earnings at $1.92 per share on revenue of $5.18 billion. Bunge (NYSE: BG ) is projected to report quarterly earnings at $2.55 per share on revenue of $13.61 billion. Yum Brands (NYSE: YUM ) is likely to report quarterly earnings at $1.09 per share on revenue of $1.88 billion. Crown Crafts (NASDAQ: CRWS ) is likely to report quarterly earnings at $0.24 per share on revenue of $18.80 million.

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally

JMP Securities reissued their buy rating on shares of PolyPid (NASDAQ:PYPD) in a report issued on Thursday morning, Analyst Ratings Network reports. JMP Securities currently has a $15.00 price objective on the stock. Separately, Zacks Investment Research upgraded shares of PolyPid from a hold rating to a buy rating and set a $8.50 target price []

PolyPid Ltd. (NASDAQ:PYPD) was the target of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 28,200 shares, a growth of 30.0% from the October 14th total of 21,700 shares. Currently, 0.2% of the shares of the company are sold short. Based on an []